1,720,983 research outputs found
sj-docx-1-pat-10.1177_2632010X221102054 – Supplemental material for Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
No full textSupplemental material, sj-docx-1-pat-10.1177_2632010X221102054 for Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status by Jim Hsu, Joseph F Annunziata, Ethan Burns, Eric H Bernicker, Randall J Olsen and Jessica S Thomas in Clinical Pathology</p
sj-jpg-2-pat-10.1177_2632010X221102054 – Supplemental material for Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
No full textSupplemental material, sj-jpg-2-pat-10.1177_2632010X221102054 for Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status by Jim Hsu, Joseph F Annunziata, Ethan Burns, Eric H Bernicker, Randall J Olsen and Jessica S Thomas in Clinical Pathology</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Abstract CT064: Trial of SBRT and in-situ gene therapy followed by nivolumab in metastatic non-small cell lung carcinoma (ENSIGN)
No full textAbstract
The programmed death-1 (PD-1) pathway represents a major tumoral immune resistance mechanism. Although anti-PD-1 blockade with nivolumab has shown great promise in the treatment of metastatic squamous and non-squamous non-small cell lung carcinoma (NSCLC), only a minority of patients derive benefit. Viral vector-based gene therapy such as adenoviral vector-mediated herpes simplex virus tyrosine kinase (ADV/HSV-tk) plus (+) valacyclovir has been shown to induce antitumor immune activity by increasing natural killer cell proliferation and cytotoxicity, cytokine stimulatory activity, and lymphocytic infiltrate. Radiation therapy also augments endogenous antitumor immune responses and often leads to systemic responses at distant sites. This phenomenon, known as the abscopal effect, has been attributed to the induction and enhancement of antitumor immune responses. Based on these findings, we are conducting a Phase II window of opportunity trial of stereotactic body radiation therapy (SBRT) and ADV/HSV-tk in situ gene therapy followed by nivolumab in metastatic squamous or non-squamous NSCLC (NCT02831933). We hypothesize that ADV/HSV-tk + valacyclovir and SBRT will boost endogenous immune-mediated antitumor activity and neoantigen expression, thereby improving the response to nivolumab treatment. The primary endpoint is the objective response rate, and secondary endpoints are duration of response, overall and progression-free survival rates, and antitumor activity. Correlative studies include evaluation of abscopal effect and immune response. ADV/HSV-tk (5 x 1011 viral particles) will be injected intratumorally on Day 0. Valacyclovir (2 g orally 3 times/day) and SBRT (30 Gy; 6 Gy X 5 fractions) will be administered from Day 1 to Day 15 and Day 2 to Day 16, respectively. Nivolumab at a dose of 240 mg will be administered intravenously every 2 weeks starting on Day 17 of the study and continuing until disease progression or unacceptable toxicity. Male or female patients with histologically or cytologically confirmed metastatic squamous or non-squamous NSCLC that has progressed on or after platinum-based chemotherapy or on or after single agent immune checkpoint therapy will be eligible for enrollment. Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab. Other eligibility criteria include Eastern Cooperative Oncology Group performance status of 0-1, life expectancy ≥ 6 months, evaluable or measurable disease (RECIST 1.1), target lesion of suitable diameter (at least 1 cm) for SBRT, and non-target lesion of at least 1 cm for abscopal effect evaluation. Twenty-nine patients will be enrolled, and enrollment is expected to begin in February 2017.
Citation Format: Eric H. Bernicker, Bin S. Teh, Brian Butler, Jenny C. Chang. Trial of SBRT and in-situ gene therapy followed by nivolumab in metastatic non-small cell lung carcinoma (ENSIGN) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT064. doi:10.1158/1538-7445.AM2017-CT064</jats:p
- …
